Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OMHE’s_Licensed_Medical_Marijuana_Cultivation_Plan
On 2/9/2017 OMHE CEO released 1st letter (Click Here to Read) to shareholders and most of the promises have been fulfilled as we can see Here and here in this 11/14/2017 CEO's 2nd Letter. One more the most important promise was licensed medical marijuana cultivation plan and I am expecting that will be implemented in next few months.
From 2/9/2017 Letter
OMHE_has_(1)R&D_Biotech_Lab_(2)Scientists_(3)MMJ_License_(4)Developed_Cannabinoid_based_Medicine
Status, as of Nov 2017
(1) Specialty Pharmaceuticals –----------------- Completed - Click here to see proof
(2) Anti-Aging Brands –---------------------------- Completed - Click here to see proof
(3) Therapeutic Cannabis Products –---------- Completed - Click here to see proof
(4) Licensed Medical Marijuana Cultivation – INPROGRESS – WILL BE ANNOUNCED SOON
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
OMHE_Became_The_Leader_Of_Cannabinoid_based_Therapy&Medicine_Research
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
BABA_Kraken_OMHE_is_fulfilling_One_Promise_After_Another_StockPrice_will_Continue_to_Rise
FY2017 and 1Q18 reports have been filed.
You had conveyed OMHE business plan in Feb 2017. Since then OMHE acquired new business, inducted scientists, established advanced Biotech R&D lab, conducting research to develop cannabinoid-based drug therapies. Latest update was provided on 11/14/2017: cannabinoid-based pain treatment medicine is ready to be marketed; talks are underway with large European companies. Target markets include North America, Europe, Australia and Asia.
Folks! OMHE will hit $1 soon. Be patient! Don't Settle for Less.
OMHE_is_the_Leader_of_Cannabinoid_Based_Pain_Treatment_Therapy/Medicine
Link To News
OMHE is Heading to One Dollar PPS
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To 11/14/2017 News
OMHE IS THE LEADER OF THE MMJ BIOTECH INDUSTRY
* OMHE OTCQB Uplist is imminent
* OMHE had provided a detailed plan on 2/9/2017
* OMHE planned to acquire more businesses
* OMHE reported solid $4.6Million FY2017 Revenue
* OMHE promised to release FY2017, which they did!
* OMHE - No Yield sign anymore!
* OTC confirmed that OMHE is current, shows a big positive confidence in OMHE filings
* OMHE CEO has credentials and experience to envision and execute a successful business plan Read here then decide Also, his current track record proves that!
* OMHE owns and operates licensed highly lucrative pharmaceutical, medical and wellness business
* As Promised OMHE CEO released follow up to 2/9/2017 letter on 11/14/2017
* OMHE has developed cannabinoid biotherapeutics/medicine
* OMHE to Collaborate/joint venture with one of the largest European cannabis companies.
* Licensed Medical marijuana cultivation about to start.
* OMHE PPS is ready to rise to $ 1
OMHE's Performance is on the TOP!
From 17Q2 10-Q:
OMHE_FY2017_Rev_4.6Million_In_Final_Stages_of_Cannabinoid_based_Chronic_Pain_Treatment_Medicine
Link To The Latest, 11/14/2017 OMHE CEO Letter
Omni Health, Inc. Releases Letter to Shareholders
•November 14, 2017
Comment
MIAMI, FL--(Marketwired - Nov 14, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health's annual revenues have grown to more than $4.6 million; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I'm working diligently to create a cycle of perpetual growth that over time will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., ( OTC PINK : OMHE ) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
*********NEXT HUGE NEWS SOON**********
OMHE_Has_Solid_Base_PPS_Cannot_Be_Manipulated_From_Now_On_PPS_Will_Keep_Rising
OMHE has huge potential and entry at this point will maximize the gain. OMHE PPS has risen steadily in past 2 weeks and exponential rise is on the horizon due to upcoming big announcements as discussed by OMHE CEO in this Nov. 2017 Letter to Shareholders
GLTA
BIG_Announcement_OMHE_is_Diving_into_$36Billion_Pain_Management_GlobalMarket
Link To News
Andrey_I_am_Happy_With_You_As_an_OMHE_Shareholder_Dollar_Land_is_Near
FY2017 and 1Q18 reports have been filed.
You had conveyed OMHE business plan in Feb 2017. Since then OMHE acquired new business, inducted scientists, established advanced Biotech R&D lab, conducting research to develop cannabinoid-based drug therapies. Latest update was provided on 11/14/2017: cannabinoid-based pain treatment medicine is ready to be marketed.
I am satisfied with OMHE's progress!!
OMHE R&D Team
On 5/10/2017, SAB was formed and CEO had promised to expand "this Board with an elite group of industry, academic, and government experts" and on 6/1/2017, OMHE showed its commitment by inducting 2nd member to SAB. OMHE updated about another scientist in 11/14/2017 Letter.
SAB Member # 1: Dr. Arkady Uryash, MD, PhD
Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors.
SAB Member # 2: Dr. Lawrence E. Samuels, MD
Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
SAB Member # 3: Dr. Karyemaitre Aliffe, MD
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
SOON OMHE WILL LEAD ALL OTC STOCKS
* OMHE OTCQB Uplist is imminent
* OMHE had provided a detailed plan on 2/9/2017
* OMHE planned to acquire more businesses
* OMHE reported solid $4.6Million FY2017 Revenue
* OMHE promised to release FY2017, which they did!
* OMHE - No Yield sign anymore!
* OTC confirmed that OMHE is current, shows a big positive confidence in OMHE filings
* OMHE CEO has credentials and experience to envision and execute a successful business plan Read here then decide Also, his current track record proves that!
* OMHE owns and operates licensed highly lucrative pharmaceutical, medical and wellness business
* As Promised OMHE CEO released follow up to 2/9/2017 letter on 11/14/2017
* OMHE has developed cannabinoid biotherapeutics/medicine
* OMHE PPS is ready to rise to $1!
For_Any_New_Trader_Joining_Us_Here_On_This_Board
Link To The Latest, 11/14/2017 OMHE CEO Letter
Omni Health, Inc. Releases Letter to Shareholders
•November 14, 2017
Comment
MIAMI, FL--(Marketwired - Nov 14, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health's annual revenues have grown to more than $4.6 million; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I'm working diligently to create a cycle of perpetual growth that over time will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., ( OTC PINK : OMHE ) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
Signs_Are_OMHE_is_Ready_For_OTCQB_Uplist_And_After_That_HUGE_PPS_UPLIFT
Look for Green check mark and date (10/26/2017) i.e. when company's profile was verified on OTC website:
https://www.otcmarkets.com/stock/OMHE/profile
OTC Filings are up to date. OTCQB Certification can be filed anytime now, which is the last step before OTCQB Uplist!!
OMHE_Cannabinoid_based_Therapy&Medicine_Research
Link To The News
OMHE_Became_The_Leader_Of_Cannabinoid_based_Therapy&Medicine_Research
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
OMHE’s_ Cannabidiol_Products_To_Be_Exported_To_Europe._Capturing_Pain_Treatment_Market
Link To 11/14/2017 OMHE CEO Letter
OMHE_has_(1)R&D_Biotech_Lab_(2)Scientists_(3)MMJ_License_(4)Developed_Cannabinoid_based_Medicine
Status, as of Nov 2017
(1) Specialty Pharmaceuticals –----------------- Completed - Click here to see proof
(2) Anti-Aging Brands –---------------------------- Completed - Click here to see proof
(3) Therapeutic Cannabis Products –---------- Completed - Click here to see proof
(4) Licensed Medical Marijuana Cultivation – INPROGRESS – WILL BE ANNOUNCED SOON
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
OMHE’s_Licensed_Medical_Marijuana_Cultivation_Soon
On 2/9/2017 OMHE CEO released 1st letter (Click Here to Read) to shareholders and most of the promises have been fulfilled as we can see Here and here in this 11/14/2017 CEO's 2nd Letter. One more the most important promise was licensed medical marijuana cultivation plan and I am expecting that will be implemented in next few months.
From 2/9/2017 Letter
OMHE_is_fulfilling_one_promise_after_another_investors_confidence_is_rock_solid_a_lot_on_the_way_JUST_WATCH
OMHE is doing all in a planned manner:
1) Purchased VTCQ shell, for a $6Mil existing rev company
2) Changed to OMHE
3) Completed 17Q1, Q2 10-Qs
4) Announced CEO Name
5) Reviewed/Released 17Q1, Q2 10-Qs
6) Announced OTCQB uplist plan
7) In Feb 2017, CEO released his comprehensive vision
8) Released 17Q3 10-Q timely (within allowed extended period)
9) R&D work and uplist was in progress in the background
10) Secured $1Mil financing
11) Developed/Announced Cannabis/Biotech R&D Lab launch and lab leader's announcement
Expected upcoming BIG developments/announcements include:
12) Progress on OTCQB uplist << To Be Announced
13) Revenue Augment plan<< Partially Announced
14) FY2017 Report Release << Completed
15) Cannabinoid therapy development for pain management << In Progress
16) New Business acquisitions << To Be Announced
17) Cannabis product/medicine development in OMHE R&D Lab<< Completed-More-On-the-Way
18) News about Anti-aging product developed by its own scientist << Announced
19) Marketing/Sales/Rev generation from their own developed products << In Progress
20) Huge investments because R&D work attract big investors << To Be Announced
21) Shares restructuring << Announced – Will be filed Soon
22) Collaboration/joint venture with one of the largest European cannabis companies << In Progress
23) Licensed Medical marijuana cultivation << In Progress
OMHE has an advanced Biotech R&D lab and scientists are working in it to develop cannabinoid-based drug therapies / medicines. Clinical Trial start news will come out now any day.
Click to Read News>>>OMHE had announced all this earlier this year
OMHE’s_Licensed_Medical_Marijuana_Cultivation_Coming_Soon
On 2/9/2017 OMHE CEO released 1st letter (Click Here to Read) to shareholders and most of the promises have been fulfilled as we can see Here and here in this 11/14/2017 CEO's 2nd Letter. One more the most important promise was licensed medical marijuana cultivation plan and I am expecting that will be implemented in next few months.
From 2/9/2017 Letter
OMHE_FY2017_Rev_4.6Million_In_Final_Stages_of_Cannabinoid_based_Chronic_Pain_Treatment_Medicine
Link To The Latest, 11/14/2017 OMHE CEO Letter
Omni Health, Inc. Releases Letter to Shareholders
•November 14, 2017
Comment
MIAMI, FL--(Marketwired - Nov 14, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health's annual revenues have grown to more than $4.6 million; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I'm working diligently to create a cycle of perpetual growth that over time will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., ( OTC PINK : OMHE ) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
For_Any_New_Trader_Joining_Us_Here_On_This_Board
Link To The Latest, 11/14/2017 OMHE CEO Letter
Omni Health, Inc. Releases Letter to Shareholders
•November 14, 2017
Comment
MIAMI, FL--(Marketwired - Nov 14, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health's annual revenues have grown to more than $4.6 million; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I'm working diligently to create a cycle of perpetual growth that over time will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., ( OTC PINK : OMHE ) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
Huge_News>OMHE_Ready_To_Capture_World’s_Cannabinoid_Based_Pain_Treatment_Market
Link To News
OMHE_Became_The_Leader_Of_Cannabinoid_based_Therapy&Medicine_Research
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
OMHE_Licensed_Medical_Marijuana_Cultivation_COMING_SOON
On 2/9/2017 OMHE CEO released 1st letter (Click Here to Read) to shareholders and most of the promises have been fulfilled as we can see Here and here in this 11/14/2017 CEO's 2nd Letter. One more the most important promise was licensed medical marijuana cultivation plan and I am expecting that will be implemented in next few months.
From 2/9/2017 Letter
OMHE_OTCQB_Upgrade_&_Licensed_Medical_Marijuana_Cultivation_Updates_SOON
Link To Nov. 2017 News
OMHE_has_(1)R&D_Biotech_Lab_(2)Scientists_(3)MMJ_License_(4)Developed_Cannabinoid_based_Medicine
Status, as of Nov 2017
(1) Specialty Pharmaceuticals –----------------- Completed - Click here to see proof
(2) Anti-Aging Brands –---------------------------- Completed - Click here to see proof
(3) Therapeutic Cannabis Products –---------- Completed - Click here to see proof
(4) Licensed Medical Marijuana Cultivation – INPROGRESS – WILL BE ANNOUNCED SOON
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
OMHE is The Champion of 6 Pharmaceutical Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies
6) Global Wellness
OMHE is a relatively new public company.Now they have money, talent, R&D lab, and plan. Execution is in progress....... Also, OTCQB upgrade is on the way!
OMHE’s_ Cannabidiol_Products_To_Be_Exported_To_Europe._Capturing_Pain_Treatment_Market
Link To 11/14/2017 OMHE CEO Letter
OMHE R&D Team
On 5/10/2017, SAB was formed and CEO had promised to expand "this Board with an elite group of industry, academic, and government experts" and on 6/1/2017, OMHE showed its commitment by inducting 2nd member to SAB. OMHE updated about another scientist in 11/14/2017 Letter.
SAB Member # 1: Dr. Arkady Uryash, MD, PhD
Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors.
SAB Member # 2: Dr. Lawrence E. Samuels, MD
Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
SAB Member # 3: Dr. Karyemaitre Aliffe, MD
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
OMHE’s_Licensed_Medical_Marijuana_Cultivation_Plan
On 2/9/2017 OMHE CEO released 1st letter (Click Here to Read) to shareholders and most of the promises have been fulfilled as we can see Here and here in this 11/14/2017 CEO's 2nd Letter. One more the most important promise was licensed medical marijuana cultivation plan and I am expecting that will be implemented in next few months.
From 2/9/2017 Letter
OMHE_will_trade_in_10_20cents_range_in FewDays_And_CloseTo_One_Dollar_in_FewWeeks
OMHE is doing all in a planned manner:
1) Purchased VTCQ shell, for a $6Mil existing rev company
2) Changed to OMHE
3) Completed 17Q1, Q2 10-Qs
4) Announced CEO Name
5) Reviewed/Released 17Q1, Q2 10-Qs
6) Announced OTCQB uplist plan
7) In Feb 2017, CEO released his comprehensive vision
8) Released 17Q3 10-Q timely (within allowed extended period)
9) R&D work and uplist was in progress in the background
10) Secured $1Mil financing
11) Developed/Announced Cannabis/Biotech R&D Lab launch and lab leader's announcement
Expected upcoming BIG developments/announcements include:
12) Progress on OTCQB uplist << To Be Announced
13) Revenue Augment plan<< Partially Announced
14) FY2017 Report Release << Completed
15) Approval of OTCQB uplist application << In Progress
16) New Business acquisitions << To Be Announced
17) News about Cannabis product development in OMHE R&D Lab<< Completed-More-On-the-Way
18) News about Anti-aging product developed by its own scientist << Announced
19) Marketing/Sales/Rev generation from their own developed products << In Progress
20) Huge investments because R&D work attract big investors << To Be Announced
21) Shares restructuring << Announced – Will be filed Soon
22) Collaboration/joint venture with one of the largest European cannabis companies << In Progress
Thanks for the reminder..wallstreetbuyer
OMHE_2cents+_PPS_is_A_Gift____Enjoy_Your_Thanksgiving_Holiday
Status, as of Nov 2017
(1) Specialty Pharmaceuticals –----------------- Completed - Click here to see proof
(2) Anti-Aging Brands –---------------------------- Completed - Click here to see proof
(3) Therapeutic Cannabis Products –---------- Completed - Click here to see proof
(4) Licensed Medical Marijuana Cultivation – INPROGRESS – WILL BE ANNOUNCED SOON
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
OMHE PPS Ready to Rise to $1
OMHE_Became_The_Leader_Of_Cannabinoid_based_Therapy_&_Medicine_Research
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To 11/14/2017 News
OMHE has an advanced Biotech R&D lab and scientists are working in it to develop cannabinoid-based drug therapies / medicines. Clinical Trial start news will come out now any day.
Click to Read News>>>OMHE had announced all this earlier this year